These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26224766)

  • 21. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.
    Bonds AC; Sampson NS
    Curr Opin Chem Biol; 2018 Jun; 44():39-46. PubMed ID: 29906645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.
    Zhang S; Shi W; Feng J; Zhang W; Zhang Y
    Emerg Microbes Infect; 2017 Apr; 6(4):e28. PubMed ID: 28442751
    [No Abstract]   [Full Text] [Related]  

  • 24. Antituberculosis activity of the molecular libraries screening center network library.
    Maddry JA; Ananthan S; Goldman RC; Hobrath JV; Kwong CD; Maddox C; Rasmussen L; Reynolds RC; Secrist JA; Sosa MI; White EL; Zhang W
    Tuberculosis (Edinb); 2009 Sep; 89(5):354-63. PubMed ID: 19783214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 26. In silico analyses for the discovery of tuberculosis drug targets.
    Chung BK; Dick T; Lee DY
    J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
    Srivastava S; Gumbo T
    Curr Pharm Des; 2011; 17(27):2881-8. PubMed ID: 21834761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using animal models to develop new treatments for tuberculosis.
    Nuermberger E
    Semin Respir Crit Care Med; 2008 Oct; 29(5):542-51. PubMed ID: 18810687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
    Gawad J; Bonde C
    Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quest for the holy grail: new antitubercular chemical entities, targets and strategies.
    Huszár S; Chibale K; Singh V
    Drug Discov Today; 2020 Apr; 25(4):772-780. PubMed ID: 32062007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
    Ioerger TR; Sacchettini JC
    Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
    Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New antitubercular drugs].
    Krasucka-Kluźniak A
    Pneumonol Pol; 1990; 58(4-5):163-6. PubMed ID: 2168041
    [No Abstract]   [Full Text] [Related]  

  • 34. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 35. Trends in discovery of new drugs for tuberculosis therapy.
    Riccardi G; Pasca MR
    J Antibiot (Tokyo); 2014 Sep; 67(9):655-9. PubMed ID: 25095807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational models for tuberculosis drug discovery.
    Ekins S; Freundlich JS
    Methods Mol Biol; 2013; 993():245-62. PubMed ID: 23568475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
    Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
    mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Host-pathogen systems for early drug discovery against tuberculosis.
    Trofimov V; Costa-Gouveia J; Hoffmann E; Brodin P
    Curr Opin Microbiol; 2017 Oct; 39():143-151. PubMed ID: 29179041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 40. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
    Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.